Evommune is focused on discovering and developing novel therapies designed to treat and halt the progression of chronic inflammatory disease.

Evommune

Evommune | 2,818 followers on LinkedIn. Inventing ways to treat inflammatory diseases, developing therapies that address symptoms and halt progressive disease. | Chronic inflammatory diseases are the most significant cause of death in the world, and those who live with them have a reduced quality of life.

Many immunology-focused medications give patients a temporary fix to a longer-term problem—addressing symptom control rather than the root cause of disease.

Evommune is different.

Emily Ip

Luis Peña

Research and Development Leader

Jeegar Patel, Ph.D.

Driven corporate development and strategy leader

Lauren Krusius

Thanks to Nasdaq for highlighting our Series C financing and to our mission to do something about chronic inflammation. #biotech #biotechnology #lifescience

Today, we announced the closing of a $115 million Series C financing co-led by new investors RA Capital Management and Sectoral Asset Management , with participation from additional new plus existing investors. We also welcomed Derek DiRocco , PhD and François Beaubien , Ph.D. to our Board of Directors. Proceeds will be used to support the advancement of our lead clinical programs in chronic urticaria and atopic dermatitis. Learn more: https://lnkd.in/gzjbRSUA #immunology #inflammation #urticaria #biotechnology

Thanks to New York Stock Exchange #NYSE for recognizing our $115 million Series C financing. #biotech #lifescience #biotechnology

Check out CURE article on Evommune's goal in developing new and improved treatment options for patients living with chronic inflammatory diseases. #inflammation #inflammatorydiseases #biotechnology https://lnkd.in/gNpdSaHG

Evommune wishes to congratulate Eli Lilly on obtaining FDA approval for Ebglyss™ (lebrikizumab-ibkz). Several of our current Evommune colleagues played a role in its development, and are proud of its approval. Our drive to continue to deliver meaningful new medicines to patients has never been stronger. Chronic inflammation destroys lives and Evommune is here to do something about it! https://lnkd.in/gzKkPXi7

All of us at Evommune are deeply saddened by the recent passing of Dr. Marcus Maurer, a scientific collaborator at the Institute of Allergology at Charité in Berlin. #dermatology #inflammation #immunology

Evommune will be presenting a corporate update, including this week’s news on the commencement of a Phase 2 trial in adult patients with chronic inducible urticaria, at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York City. Presentation will take place on Thursday, September 5th at the Marriott Marquis.

Dermatology Times article on our Phase 2 trial in Chronic Inducible Urticaria. https://lnkd.in/gJHp65QE

EVOM

COM:EVOMMUNE

Evommune

locale

market

industry

website

crunchbase

linkedin

peer of

investor of

Metrics